A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial) by Quartier, Pierre et al.
Extended report
Ann Rheum Dis 2011;70:747–754. doi:10.1136/ard.2010.134254 747
  
Accepted 11 November 2010
Published Online First 
20 December 2010
  ABSTRACT 
  Objectives      To assess the efﬁ  cacy of the interleukin 1 
receptor antagonist anakinra in systemic-onset juvenile 
idiopathic arthritis (SJIA).   
  Methods      A multicentre, randomised, double-blind, 
placebo-controlled trial was conducted. The primary 
objective was to compare the efﬁ  cacy of a 1-month 
treatment with anakinra (2 mg/kg subcutaneous daily, 
maximum 100 mg) with a placebo between two groups 
each with 12 patients with SJIA. Response was deﬁ  ned 
by a 30% improvement of the paediatric American 
College of Rheumatology criteria for JIA, resolution of 
systemic symptoms and a decrease of at least 50% of 
both C-reactive protein and erythrocyte sedimentation 
rate compared with baseline. After month 1 (M1), 
patients taking placebo were switched to anakinra. 
Secondary objectives included tolerance and efﬁ  cacy 
assessment for 12 months, and analyses of treatment 
effect on blood gene expression proﬁ  ling.   
  Results      At M1, 8/12 responders were receiving anakinra 
and 1 responder receiving placebo (p=0.003). Ten 
patients from the placebo group switched to anakinra; 
nine were responders at M2. Between M1 and M12, six 
patients stopped treatment owing to an adverse event 
(n=2), lack of efﬁ  cacy (n=2) or a disease ﬂ  are (n=2). 
Blood gene expression proﬁ  ling at enrolment and at 6 
months’ follow-up showed one set of dysregulated genes 
that reverted to normal values in the clinical responders 
and a different set, including interferon (IFN)-inducible 
genes, that was induced by anakinra.   
  Conclusions      Anakinra treatment is effective in SJIA, at 
least in the short term. It is associated with normalisation 
of blood gene expression proﬁ  les in clinical responders 
and induces a de novo IFN signature. 
  Trial Registration Number: NCT00339157.      
  INTRODUCTION 
  Systemic-onset juvenile idiopathic arthritis (SJIA) 
is a disease of unknown aetiology characterised 
by arthritis and systemic symptoms starting before 
the age of 16.    1    The most characteristic feature at 
onset is spiking fever, which is often associated 
with an evanescent skin rash, hepatosplenomegaly 
and pericarditis. Non-steroidal anti-inﬂ  ammatory 
drugs, corticosteroids, methotrexate and antitu-
mour necrosis factor (anti-TNF) agents are often 
only partially effective.    2         3    The anti-interleukin 
6 receptor antagonist tocilizumab was effective in 
one randomised withdrawal trial.    4    Patients with a 
persistently systematically active course 6 months 
after disease onset, while receiving corticosteroid 
treatment, are at high risk of longlasting, non-
remitting or polycyclic disease.    5    
  Interleukin 1 (IL-1) has an important role in SJIA. 
In particular, serum samples from patients with SJIA 
induce IL-1β transcription on healthy peripheral 
blood mononuclear cells (PBMCs), and treatment 
with the IL-1 receptor antagonist (IL-1Ra) anakinra 
leads to the normalisation of a disease-speciﬁ  c gene 
expression proﬁ  le.    6        7    Non-controlled pilot studies 
provide evidence of dramatic, quick responses to 
anakinra in a subgroup of patients with SJIA.    6        8   –    10    
However, some patients may have a self-remitting 
course, and no placebo-controlled studies have been 
published to evaluate the effects of IL-1 blockade. 
  We therefore designed a trial aiming at assess-
ing the efﬁ  cacy of anakinra treatment, and its effect 
on blood gene expression proﬁ  ling, in patients with 
SJIA displaying active systemic disease despite cor-
ticosteroid treatment.   
  PATIENTS  AND  METHODS 
  Patients 
  This was a multicentre trial including six centres. 
Inclusion criteria were age 2–20 years, a diagno-
sis of SJIA,    1    more than 6 months’ disease duration, 
active systemic disease (disease-related fever and/
or C-reactive protein (CRP) >20 mg/l and/or ﬁ  rst 
hour erythrocyte sedimentation rate (ESR) >20) 
and signiﬁ  cant overall disease activity at day 1 (D1) 
(at least three of the following criteria: (1) physi-
cian global assessment of disease activity ≥20/100; 
(2) parent/patient assessment of disease effect on 
overall wellbeing ≥20/100; (3) Childhood Health 
Assessment Questionnaire score ≥0.375/3; (4) ≥2 
joints with active arthritis; (5) ≥2 joints with non-
irreversible limited range of motion and (6) ESR ≥30) 
despite oral prednisone or prednisolone ≥0.3 mg/kg 
or 10 mg/day (whichever was lower). Female sub-
jects entering the study were prepubescent, sexually 
inactive or required to use effective contraception. 
Exclusion criteria included previous treatment with 
an IL-1 inhibitor or any condition contraindicat-
ing immunosuppressive treatment. Intravenous or 
intra-articular steroids, immunosuppressive drugs 
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  Gene  expression  proﬁ  ling and cytokine measurements 
  Blood samples were collected in Tempus tubes (ABI, Foster City, 
California, USA) from the patients at D1, M1 and M6 and from 
age and gender-matched healthy controls.   
  Transcriptional  module-based  analysis 
  This mining strategy has been described in detail elsewhere.    14    In 
this study, RefSeq IDs were used to match probes between the 
Affymetrix U133 platform, which was used to generate the orig-
inal set of modules using PBMC expression data,    14    and Illumina 
Hu6 platform, which was used to hybridise whole blood sam-
ples from patients enrolled in this study and healthy controls. 
Unambiguous matches in Illumina were found for 2109 out of 
the 5348 Affymetrix probe sets. Illumina modules containing 
<10 genes were not included in the analysis.   
  Cytokine  multiplex  analysis 
  Serum samples were analysed using the cytokine assay kit (Bio-
Rad, Hercules, California, USA) according to the manufacturer’s 
protocol.   
    Assessment, outcome and safety measures 
  The primary objective was to compare the efﬁ  cacy  after 
1 month’s treatment with anakinra (2 mg/kg subcutaneously daily, 
maximum 100 mg) or placebo in the two groups of patients. To 
be responders to a modiﬁ  ed American College of Rheumatology 
Pediatric (ACRpedi) 30 score built for the purpose of the trial, 
patients had to fulﬁ  l the three following conditions: (1) ACRpedi 
30 response    15   ; (2) absence of disease-related fever (body tempera-
ture <38°C over the past 8 days) and (3) 50% decrease compared 
with D1 or normalisation of both CRP and ESR values. 
  Modiﬁ  ed ACRpedi 30, 50, 70 and 100 responses, assessed 
throughout the study, included an improvement of 30%, 50%, 
70% or more and 100% respectively, in at least three of the six 
core criteria for juvenile rheumatoid arthritis and a worsening of 
30 or more in no more than one of the criteria. The criteria were 
the physician’s global assessment of disease activity and the 
patient’s or the parents’ global assessment of overall wellbeing, 
the number of joints with active arthritis, the number of joints 
with limited range of motion, the Childhood Health Assessment 
Questionnaire and ESR.    15    A disease ﬂ  are was deﬁ  ned as either 
(1) a reoccurrence of disease-related fever or any systemic symp-
tom, or (2) an increase by twofold of either the ESR or CRP value, 
or (3) a worsening of ≥30% in at least three of the six ACRpedi 
core criteria and an improvement of ≥30% in no more than one 
of the criteria. If the number of joints with active arthritis was 
used as a criterion of ﬂ  are and the patient initially had no active 
joints or only one active joint, an increase in the number of joints 
with active arthritis to at least two was required. 
  We also aimed to assess the number of patients who reached 
M6 with inactive disease, as deﬁ  ned by Wallace   et al      16    under a 
daily dose of predniso(lo)ne <0.3 mg/kg or 10 mg, whichever 
was lower. 
  Adverse events (AEs) were recorded throughout the study. 
Speciﬁ  c procedures were set up for serious AEs (SAEs). This 
trial was registered at   http://www.clinicaltrials.gov   (registration 
number: NCT00339157).   
  Data  analysis 
  We expected at least 60% difference in the percentage of 
patients obtaining improvement in the anakinra-treated group 
(group 1) compared with the control group (group 2), with no 
and disease-  modifying   antirheumatic drugs (DMARDs) had to be 
stopped at least 1 month before study onset or for longer periods 
of time depending on their half-life. All patients entering the study, 
and their parents for patients aged <18, gave written informed 
consent.   
  Study  design 
  The study was approved by the local independent ethics com-
mittee and consisted of two parts (  ﬁ  gure 1  ). Part 1 was a ran-
domised, double-blind, placebo-controlled phase. At D1, eligible 
patients were randomised to receive either anakinra or placebo 
(1:1) from D1 to month 1 (M1) using a computer-generated ran-
dom list. Patients were stratiﬁ  ed by centres and randomisation 
was balanced across treatments and centres. The randomisation 
information included the randomisation number, the centre, the 
assigned treatment and the date of randomisation. Investigators, 
other caregivers, the patients and their parents remained blinded 
to the assigned treatment. The primary objective was to demon-
strate a higher proportion of responders in group 1 than group 2. 
No immunosuppressive drugs or DMARDs were allowed dur-
ing the trial. Non-steroidal anti-inﬂ  ammatory drugs and corti-
costeroids had to be taken at stable dosage for 1 month before 
D1 and until M1.   
  Part 2 was an open-label treatment period: all patients received 
anakinra after M1. Tapering the dose of corticosteroids was 
allowed after the M1 visit (reduction of 0.4–0.5 mg/kg monthly for 
daily doses of ≥1.5 mg/kg, 0.3–0.4 mg/kg for doses between 1 and 
1.5 mg/kg, 0.2–0.3 mg/kg between 0.6 and 1 mg/kg, 0.1–0.2 mg/kg 
between 0.3 and 0.6 mg/kg, ≤0.10 mg/kg for doses <0.3 mg/kg). 
  Measurement of serum amyloid A (SAA) and ferritin levels 
and the percentage of glycosylated ferritin were performed at 
D1, M1 and M6. Total ferritin concentration was measured on 
a Dimension RXL HM according to the guidelines of the manu-
facturer (Dade Behring, Paris, France). Glycosylated ferritin was 
determined according to the method of Worwood   et al  ,    11      with 
minor modiﬁ  cations as previously described.    12    Pharmacokinetic 
(PK) analyses were performed on blood taken at M2 and M6. 
Concentrations of anakinra in plasma samples were determined 
using the antibody (Ab) ELISA purchased from R&D Systems 
(Minneapolis, Minnesota, USA). 
  Patients who were naive from anti-pneumococcal immunisa-
tion received Pneumo23 immunisation at D1 in order to assess 
at M1 and M12 the effect of anakinra treatment on anti-pneu-
mococcal Ab response to ﬁ  ve capsular polysaccharides.    13      
  Figure  1         Study design. *Measurement of serum amyloid A and 
ferritin levels, assessment of the percentage of glycosylated ferritin, 
gene expression proﬁ  ling analysis and cytokine measurements. 
†Measurement of the concentration of anakinra in plasma 
(pharmacokinetic analyses). ‡Measurement of serum anti-
pneumococcal antibodies. D, day; M, month.       
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    Randomised, double-blind, placebo-controlled phase 
    Response to the primary objective and assessment of individual 
variables 
  Eight of 12 patients (67%) in group 1 and only 1 of 12 (8%) in 
group 2 were responders at M1 (p=0.003), therefore the primary 
objective of the trial was met. 
  Two patients from the control group stopped treatment after 
5 and 11 days, respectively, owing to pain from injections and 
were withdrawn from the trial after the M1 visit; one of them, a 
child who presented a marked disease ﬂ  are at D1, was the only 
responder at M1 in the control group. 
  There was a signiﬁ  cant difference in favour of group 1 in the 
number of joints with active disease, physician general assess-
ment of disease activity, CRP, ESR and SAA values at M1 com-
pared with D1 (  table 2  ).   
  A univariate analysis to explore whether any covariable might 
be associated with the response at M1 according to the treatment 
more than 10% patients improving in group 2. Given a 5% type 
I error, a 20% type II error and a two-sided Fisher exact test, 12 
patients per group were required. An intention-to-treat analysis 
was retained. 
  To explore whether each variable from the ACRpedi score, 
CRP, SAA and/or parent/patient assessment of pain were 
associated with response to treatment, the ratio (value at 
  inclusion − value at M1)/value at inclusion, was compared in 
both groups. Qualitative and quantitative data were compared 
using Wilcoxon test and Fisher exact test, respectively. The 
R statistical software was used for statistical analysis.     
  RESULTS 
    Demographic and baseline characteristics 
  Twenty-seven patients were screened for entry into the study; 
24 were eligible for randomisation (  ﬁ  gure 2A  ). Demographic 
and disease characteristics are summarised in   table 1  .       
  Figure  2       Patients’ disposition. (A) Randomised placebo-controlled, double-blind trial (until M1). (B) Open-labelled phase (from M1 to M12). Arthritis 
activity leading to treatment withdrawal (= two patients withdrawn for a disease ﬂ  are-up, at M2 and M3, respectively, and two patients withdrawn 
for a lack of response, at M4 and M5, respectively). *Two patients from the control group stopped treatment after 5 and 11 days, respectively, owing 
to pain from injections and were withdrawn from the trial after the M1 visit. †Cutaneous and digestive symptoms leading to the diagnosis of Crohn’s 
disease shortly after M2. ‡Increase of serum transaminases over ﬁ  ve times the upper limit of normal at M6. AE, adverse event; JIA, juvenile idiopathic 
arthritis; M, month; SAE, serious adverse event.     
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CD163 and several members of the S100 family). Downregulated 
transcripts encode proteins involved in antigen presentation, 
lymphocyte lineage and signalling, as well as RNA processing/
splicing and DNA modiﬁ  cation (supplementary ﬁ  gure S1B and 
table S2). Cytokine transcripts encoding IL1-β and IL-6 were not 
differentially expressed, but oncostatin (OSM) and the nega-
tive regulator of cytokine signalling 3 (SOCS3) transcripts were 
upregulated.   
    Changes in blood transcriptional signatures after 1 month 
  At M1, 522 transcripts were signiﬁ  cantly changed in patients 
treated with anakinra but not in the placebo-treated group (sup-
plementary table S3). We found a signiﬁ  cant upregulation of the 
purinergic receptor P2RX7, an ATP-gated ion channel involved 
in IL-1β processing and secretion,    17    HLA-class II genes, the pro-
teasome activator PSME2 and transcripts involved in interferon 
(IFN) signalling (SOCS1, STAT1 and STAT2). IL-1B was among 
the most signiﬁ  cantly downregulated transcripts.   
    Module-level analysis of the SJIA transcriptional signature to follow 
response to anakinra treatment 
  A recently described analysis algorithm    14    that permits com-
parison of the expression of 28 groups of transcriptionally co-
regulated genes (modules) in patients and controls was applied 
to the blood expression proﬁ  les (  ﬁ  gure 3  ). At D1, patients from 
both groups displayed fairly homogeneous modular expres-
sion patterns with signiﬁ  cant upregulation of innate immunity 
and underexpression of adaptive immunity modules. Modules 
group failed to ﬁ  nd any association. A multivariate analysis was 
not performed given the restricted number of patients.   
  Safety  and  tolerability 
  Fourteen AEs were recorded in group 1 and 13 in group 2 
(  table  3  ).  There were no SAEs.     
  Anti-pneumococcal  antibody  response 
  At M1, the levels of postvaccination Abs against ﬁ  ve pneumo-
coccal capsular polysaccharide serotypes were not signiﬁ  cantly 
different between the two groups. In group 1, 11 patients 
adequately responded to all serotypes and the 12th patient 
had a normal response to three of the ﬁ  ve serotypes (online 
  supplementary table S1).   
    Gene expression proﬁ  ling analyses 
  Samples from 21 patients were included in these analyses, as 
blood from two patients was not properly collected and one 
patient was eventually diagnosed with Crohn’s disease.   
    Baseline SJIA blood gene expression proﬁ  ling 
  Analyses of blood from 21 patients with SJIA and 21 controls 
at D1 showed the differential expression of 986 transcripts 
(supplementary ﬁ  gure S1A and table S2). Among those, some of 
the most highly upregulated encode proteins involved in innate 
immunity activation, including (1) signalling components of the 
IL-1, IL-18 and Toll-like receptors (IL-1R2, IL-18RAP, IRAK3, 
TLR5, PGLYRP1), (2) inﬂ   ammasome (CARD12/IPAF) and (3) 
anti-bacterial defence/inﬂ  ammation (DEFA1, BPI, MPO ELA2, 
  Table  1         Patients characteristics at study treatment onset   
 Characteristics    Anakinra (n = 12)    Placebo (n = 12)    All patients (n = 24) 
Demographic features
  Female,  n  (%)   7  (58)   8  (67)  15  (63)
  Age, mean value, years (SD)     9.5 (5.19)     7.5 (3.73)     8.5 (4.54)
  Disease mean duration, years (SD)     4.2 (3.33)     3.2 (1.95)     3.7 (2.73)
Systemic features
  Fever (>38°C), no. of patients (%)     4 (33.3)     5 (41.7)   9 (37.5)
  CRP, mg/l (n≤6), mean value (SD)   66 (64.40)   84 (65.74)   75 (64.35)
  ESR ﬁ  rst hour (n≤10), mean value (SD)   44 (23.37)   57 (27.85)   50 (25.89)
  SAA, mg/l (n≤6.4), mean value (SD) 366 (262) 368 (229) 367 (241)
  High serum ferritin*, no. of patients     2     3   5
Joint assessment
  Active joints, mean no. (SD) 16 (13.12)   16 (15.84)   16 (14.23)
  Joints with LOM, mean no. (SD) 16 (14.88)   17 (14.91)   17 (14.57)
Global assessments
  Physician’s VAS, mean value (SD) 63 (20.57)   57 (29.74)   60 (25.21)
  Parent’s global VAS, mean value (SD) 50 (24.39)   55 (26.51)   52 (25.04)
  Parent’s pain VAS, mean value (SD) 50 (25.73)   53 (25.89)   51 (25.28)
  CHAQ, mean value (SD) 1.67 (0.845)     1.44 (0.625)     1.55 (0.736)
Treatment with steroids (predniso(lo)ne)
  Duration, mean, years (SD) 3.9 (2.93)     2.7 (2.10)     3.3 (2.56)
  Daily dose, mean, mg/kg (SD) 0.52 (0.237)     0.66 (0.373)     0.59 (0.313)
Previous treatments with DMARDs, biological agents
  DMARD and/or biological agent, no. of patients 8   11   19
  DMARD, no biological agent, no. of patients 3     3     6
  DMARD and biological agent, no. of patients 5     8   13
  Methotrexate, no. of patients 8   11   19
  Etanercept, no. of patients 5     8   13
  Others, no. of patients (no. of DMARDs) 4 (7†)   4  (6‡)   8  (13)
      *Ferritin level was highly variable and it was elevated (>100 µg/l in patients <13 years, >200 in female patients >13 years and 
>300 in male patients >13 years) in only ﬁ  ve patients (range 347–3135 µg/l), with low glycosylated ferritin (<40%) in these ﬁ  ve 
patients (range 14–30%). 
  †Thalidomide (n=2), tocilizumab (n=2, one single infusion, phase II trial), azathioprine (n=1), ciclosporin (n=1), leﬂ  unomide (n=1). 
  ‡Azathioprine (n=2), thalidomide (n=1), tocilizumab (n=1, one single infusion, phase II trial), ciclosporin (n=1), intravenous 
immunoglobulins (n=1). 
  CHAQ, Childhood Health Assessment Questionnaire (0–3); CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; 
ESR, erythrocyte sedimentation rate; LOM, joints with limitation of passive motion; SAA, serum amyloid A; VAS, visual assessment 
(0–100 mm scale) of disease activity by the physician, disease effect on overall wellbeing and pain by the parents.     
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responded to treatment (  ﬁ  gure 3  ). Of the four non-responders, 
one patient was later diagnosed with Crohn’s disease and blood 
from another patient was not properly collected; the two other 
patients did not show dysregulation of the modules at baseline 
and remained the same at M1. The modular alterations corrected 
in responders include transcripts within the platelet (M1.2), cyto-
toxic (M2.1) and erythropoiesis (M2.3) modules. None of these 
modules changed in the placebo group, therefore supporting the 
including myeloid linage (M1.5 and M2.6), neutrophil (M2.2) 
and inﬂ   ammation (M3.2 and 3.3) related transcripts were 
upregulated. Modules associated with erythrocytes (M2.3) 
and platelets (M1.2) were also upregulated. Conversely, mod-
ules containing transcripts related to lymphoid/T-cell lineage 
(M2.8 and M3.8), B cells (M1.3), T cells (M1.4) and cytotoxic 
cells (M2.1) were downregulated. At M1, several modular 
alterations were corrected in the anakinra-treated patients who 
  Table  3      Adverse  events  (AEs)  
Adverse event
  Part A (double-blind)    Part 2 (M1–12) (open label) 
 Group  1   Group  2 
 Anakinra   Anakinra   Placebo 
Number of patients (patient-years*) 12 (1) 12 (1)   22 (15.17)
Any AE, no. (/patient-year)† 14 (14) 13 (13)   89 (5.71)
Serious AE, no. (/patient-year)   0 (0)   0  (0)   5  (0.33)‡
Pain to injection, no. (/patient-year)   8 (8)   6 (6)   15 (0.99)
Post-injection  erythema,  no.  3  1   6  (0.40)
Infections, no. (/patient-year)   2 (2)   2 (2)   44 (2.90)
  ENT infections and laryngitis, no.   1   1   20
  Bronchitis,  no.  0  0   8
  Gastroenteritis,  no.  1  1   3
  Skin  infections,  no.  0  0   4
  Other  infections,  no.  0  0   9§
Vomiting,  abdominal  pain,  no.  0  1   9
Other AE¶, no. (/patient-year)  0  (0)  2  (2)  10  (0.66)
      *Patient-years = 12 patients in each group followed up for 1 month during the double-blind phase, 22 patients exposed to study treatment for a total of 182 months during the  
open-label phase (eight patients were withdrawn from the trial between M1 and M6). 
  †Disease activity/ﬂ  ares was not systematically recorded as an AE. 
  ‡Infections in four patients, vertebral collapse in one patient (these ﬁ  ve patients continued the trial), skin and digestive symptoms leading to the diagnosis of Crohn’s disease in one 
patient. 
  §Varicella (n=3), vulvar candidiasis (n=2), isolated fever (n=2), atypical pneumonitis, urinary tract infection. Favourable outcome in all cases, no patient withdrawn from the trial. 
  ¶Skin lesions (n=5), haematuria (n=2), back pain (n=2), dental fracture, asthenia, vertigo.     
  Table  2      Responses  at  month  1  
Response
 Group  1   Group  2 
 p  Value* 
  Anakinra (n = 12)    Placebo (n = 12) 
  Number of responders (%) 
Primary objective (modiﬁ  ed ACRpedi 30)†  8  (67)   1  (8) 0.003
Systemic symptoms responders†  8  (67)   1  (8) 0.003
Primary objectives used in other trials
  ACRpedi 30 responders 11 (92)     7 (58) 0.059
  ACRpedi 30 and no fever‡ 11  (92)   6  (50) 0.025
  ACRpedi 30, no fever and CRP <15 mg/l§ 10  (83)   3  (25) 0.004
Modiﬁ  ed ACRpedi 50, 70 and 100 response†
  Modiﬁ  ed ACRpedi 50 responders   7 (58)     0 0.005
  Modiﬁ  ed ACRpedi 70 responders   5 (42)     0 0.038
  Modiﬁ  ed ACRpedi 100 responders   0     0 1
  Response to individual variables   Mean variation from D1 to M1 (%)   p Value¶ 
CRP −71 −16 0.001
ESR −64 −18 0.002
SAA −70 −2 <0.001
Number of active joints −46 −18 0.040
Number of joints with LOM −36 −20 0.148
CHAQ −37 −9 0.236
Physician’s disease activity assessment** −63 −20 0.002
Parent/patient’s global assessment** −36 −23 0.544
Parent/patient’s assessment of pain** −29 −21 0.219
   * χ   2    Test. 
  †Body temperature <38°C for more than 7 days, CRP and ESR normalised or decreased by at least 50% (=systemic symptoms 
responders) and also, in responders to the trial primary objective, ACRpedi 30, 50, 70 or 100 (whichever level is indicated) response 
compared with D1. 
  ‡Body temperature <38°C for more than 7 days and ACRpedi 30 response compared with D1. 
  §Body temperature <38°C for more than 7 days, CRP <15 mg/l and ACRpedi 30 response compared with D1 as in a recent trial with 
the anti-interleukin 6 receptor antibody tocilizumab. 
  ¶Mann–Whitney test. 
  **Using a visual analogue scale (0–100 mm). 
  ACRpedi 30, American College of Rheumatology Pediatric 30 response; CHAQ, Childhood Health Assessment Questionnaire; CRP, 
C-reactive protein; ESR, erythrocyte sedimentation rate; LOM, joints with limitation of passive motion; SAA, serum amyloid A.     
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  The dose of predniso(lo)ne had been reduced after the M1 
visit in accordance with the protocol recommendations in all 
the responders who continued the trial (eight patients, all from 
group 1) and in seven other patients (four patients from group 1 
and three patients from group 2) who had shown some improve-
ment (investigator’s decision). Three responders from group 1 in 
whom the dose of corticosteroids had been reduced were not 
responders at M2 anymore. 
  The dose of corticosteroids was then either maintained stable 
or reduced in accordance with the protocol recommendations at 
each visit (supplementary table S4). 
  Seventeen patients continued the trial until M6. Their mean 
daily dose of predniso(lo)ne was 0.18 mg/kg (median 0.16, 
validity of the data at D1. We also observed the coordinated 
upregulation of type I IFN-inducible transcripts (M3.1) in the 
anakinra- but not in the placebo-treated group.       
  Open-label  phase 
  Twenty-two patients entered the second phase of the study 
(    ﬁ  gure 2B  ). Nine out of 10 patients from group 2 who switched 
to anakinra at M1 responded at M2. PK analyses revealed a trend 
towards lower anakinra concentrations at M2 and M6 in patients 
with lower weight and those who had failed to respond to anak-
inra after 1 month (residual anakinra concentration of 45.5 ± 51  ng/
ml (range 20–122) vs 136.5 ± 106 ng/ml (range 20–353) in respond-
ers), but overall this difference was not signiﬁ  cant. 
  Figure  3         Modular analysis. (A) Annotated module map of patients with systemic-onset juvenile idiopathic arthritis (SJIA) at D1, M1 and M6. 
Expression levels in patients were compared with those of healthy controls. Spots indicate the proportion of genes that were signiﬁ  cantly changed 
for each module (Mann–Whitney rank test, p<0.05). The black outline indicates the core signature common in the two groups of patients at D1. (B) 
Forty-nine representative genes from the module 3.1 were rearranged by hierarchical clustering in order to reveal differential expression. Expression 
values are normalised for each gene to the healthy group. Transformed expression levels are indicated by colour scale, with red representing relatively 
high expression and blue indicating relatively low expression. (C) Levels of inducible proteins IP10 and TRAIL were measured in the serum of 
patients with SJIA at D1 and M6. All results were analysed using a paired t-test. (D) SOCS3 expression was measured in whole blood of patients by 
microarray at D1 and M6. Results were analysed using a paired t-test. D, day; M, month.       
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the study design that precluded the use of associated DMARDs 
and allowed tapering of the corticosteroid dose at an early stage, 
a strategy designed to minimise the risk of treatment-related 
complications. 
  This study has limitations owing to the small number of 
patients and the short duration of the double-blind phase. In 
particular, we were unable to properly assess which patients’ 
characteristics might predict response to treatment. In recent 
reports, the absence of small joint involvement, a smaller num-
ber of joints with active disease and an increased absolute 
neutrophil count were reported to be predictive of response to 
anakinra.    9        10    
  No severe infections occurred in this trial and anti-pneumo-
coccal Ab response was not affected by anakinra treatment. 
However, severe infections have been reported under anakinra 
in adults with rheumatoid arthritis.    19    One patient here was 
diagnosed with inﬂ   ammatory bowel disease, a complication 
reported in some patients initially diagnosed with JIA and treated 
with anti-TNF agents.    3        20        21    An additional patient experienced a 
sudden rise in serum transaminases. In order to draw deﬁ  nitive 
conclusions about the safety of anakinra in SJIA, further studies 
with larger numbers of patients and longer follow-up need to be 
implemented. 
  As expected, the ex vivo genomic analysis of patient blood at 
D1 showed upregulation of transcripts related to innate immu-
nity and haematopoiesis (supplementary table S2). Although 
several hereditary and sporadic IL-1β-mediated diseases involve 
alterations in NLRP3 inﬂ  ammasome components,    22    no altered 
expression of NLRP3 inﬂ   ammasome-related transcripts was 
observed. However, two different ﬂ  agellin receptors (CARD12 
and TLR5) were signiﬁ  cantly upregulated in the majority of 
patients at D1 (supplementary table S2) and normalised in the 
responder group at M6 (supplementary table S5). Whether 
the triggering of ﬂ  agellin receptors is involved in the patho-
genesis of SJIA remains to be elucidated. Alterations in the 
blood gene expression proﬁ  les of patients with SJIA at the time 
of randomisation were highly reproducible in the treatment 
and placebo groups. This was best visualised using a strategy 
based on the analysis of modules composed of transcription-
ally co-regulated genes.    14    Longitudinal changes correlating 
with disease resolution were found upon follow-up. Changes 
probably induced by treatment, regardless of clinical response, 
were also identiﬁ  ed. Strikingly, an upregulation of type I IFN-
regulated transcripts, which is not a feature of untreated SJIA,    7    
    23   –    25    was induced in the majority of anakinra-treated patients 
at M1 and M6. Accordingly, two IFN-inducible proteins were 
also signiﬁ  cantly upregulated in the serum samples of patients 
at M6. The molecular and cellular basis for an IL-1 β/type I 
IFN cross-regulation in SJIA remains unknown. Inhibition of 
type I IFN signalling by IL-1β might occur through the induc-
tion of SOCS3, which is a negative regulator of IL-1-dependent 
acute inﬂ   ammatory arthritis and osteoclast generation.    26        27    
Conversely, type I IFN decreases IL-1β and induces IL-1Ra 
production by PBMCs in vitro.    28    A similar cross-regulation 
has been described for type I IFN and TNFα. Thus, patients 
with SJIA treated with TNF antagonists develop a blood IFN 
signature.    29    Furthermore, a signiﬁ  cant proportion of patients 
with rheumatoid arthritis and Crohn’s disease treated with 
TNF antagonists develop anti-nuclear Abs and some of them 
display symptoms of systemic lupus erythematosus, a type I 
IFN-mediated disease.    29    Whether the upregulation of type I 
IFN-inducible genes in anakinra-treated patients could have 
clinical consequences through the triggering of adaptive immu-
nity remains to be determined. 
range 0–0.58); the six responders at M6 had a daily prednisone 
dose of <10 mg or 0.3 mg/kg. These six patients, whose mean 
predniso(lo)ne dose at enrolment was 0.51 mg/kg (SD 0.32), 
were all responders to 1 month of anakinra treatment and had 
already achieved ACRpedi 50 or 70 improvement at this stage. 
  Sixteen patients reached M12; among seven responders, six 
had stopped corticosteroid treatment and ﬁ  ve of them had inac-
tive disease. 
  Safety  and  tolerability 
  Six patients developed a SAE. Four infections and one vertebral 
collapse had a favourable outcome and these ﬁ  ve patients con-
tinued the trial; one patient was diagnosed with Crohn’s disease 
shortly after M2 and withdrawn from the trial. This patient ini-
tially belong to group 1; he was a non-responder at M1; how-
ever, minor improvement had led the treating doctor to start 
tapering the dose of prednisone at this stage. 
  Other AEs mainly consisted of non-severe injection-site reac-
tions and common infections ( table 3 ). One patient stopped anak-
inra owing to a sudden increase in serum transaminases at M6.   
    Anti-pneumococcal (Pneumo23) antibody response 
  At M12, 12 patients were tested and an adequate Ab response 
was maintained in all cases (supplementary table S1).   
    Changes in gene expression proﬁ  ling at M6, modular analysis and 
correlation with clinical response to anakinra 
  Expression of more than 500 transcripts changed signiﬁ  cantly in 
the six patients who responded to anakinra at M6 (supplemen-
tary table S5). 
  The modular analysis of responders at M6 (n=6) showed 
the normalisation of 11/13 original modular alterations, while 
non-responders still showed altered expression of 12 of them 
(  ﬁ  gure  3A  ). Interestingly, overexpression of type I IFN-inducible 
genes (module 3.1) was observed in every group after   initiation 
of anakinra treatment (both at M1 and M6) regardless of the 
clinical response (  ﬁ  gure 3B  ). To support the validity of the tran-
scriptional data, we measured the protein levels of two IFN-
inducible proteins (IP10 and TRAIL) and found that they were 
signiﬁ  cantly increased in the serum of anakinra-treated patients 
at M6 (  ﬁ  gure 3C  ). Accordingly, SOCS3 expression, which could 
explain the cross-regulation of IL-1β and type I IFN, was down-
regulated in the majority of patients at M6 (  ﬁ  gure 3D  ).       
  DISCUSSION 
  This double-blind, placebo-controlled study demonstrated 
the efﬁ   cacy of anakinra in treating corticosteroid-dependent 
patients with SJIA, as a signiﬁ   cantly higher proportion of 
responders was observed after 1 month of treatment compared 
with placebo. However, a loss of response was observed in 
most patients over time. 
  The efﬁ  cacy of anakinra treatment in SJIA, at least in the short 
term, concorded with previous reports.    6        8   –    10    However, the only 
other placebo-controlled trial testing anakinra in JIA showed 
no signiﬁ  cant improvement versus placebo,    18    illustrating that 
marked response to IL-1 inhibition is not characteristic of all 
JIA subtypes. The lack of sustained response in several patients 
may have been related to several factors. First, most patients 
had diffuse polyarthritis at enrolment but no fever; as previously 
reported,    9    anakinra seemed less effective on the arthritis than on 
systemic features. Second, PK data suggested that low-weight 
children might have beneﬁ  ted from a higher anakinra dosage. 
Third, we included patients with active SJIA, steroid-depen-
dency and a minimal disease duration of 6 months, therefore 
difﬁ  cult to treat    5   ; loss of responses may have been favoured by 
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  In conclusion, a signiﬁ  cant proportion of patients with SJIA 
responded to IL-1 blockade as dramatically as patients with 
autoinﬂ  ammatory syndromes, conﬁ  rming a key role for IL-1 in a 
wide spectrum of diseases.    30    Furthermore, clinical response and 
cytokine cascades induced upon IL1 blockade can be followed 
using blood gene expression proﬁ  ling.     
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